Chile is an attractive market for Latin American pharmaceutical exports.
Chile is politically stable, has an ageing population, and has high per-capita health spending that allows pharmaceutical exports to Chile.
The total estimated size of the market is a modest but high-quality one, at around $2.5 to $3 billion,[1] by regional standards.
What most easy-entry pitches omit is the regulatory reality: Chile has extensive rules and is a harder market than regional neighbours.
Chile’s medicines agency is considered a PAHO regional reference authority. Plus, foreign manufacturers can neither register products directly nor enjoy retail access.
Access is concentrated and restricted. Exporters often discover Chile pharmaceutical market entry is not as easy as other LATAM opportunities.
This guide is for the Indian export heads, regulatory affairs professionals, and business-development managers who are deciding if pharmaceutical exports from India to Chile are a worthy, cost-effective opportunity for this year’s LATAM plans. If so, what is the best way to achieve this?
Why Chile Is Worth the Effort
A small, stable, high-value market
Chile is a small market. Estimates put total pharmaceutical sales in the country between US$2.5 and US$3 billion.
These figures are approximate because they depend on the inclusion of OTC, hospital, and institutional segments.
More recent market data from the Indian Embassy places the retail price of sales in Chile between US$2.4 and US$3.2 billion[2] for the period 2022 to 2024, and growing to around US$3.1 billion by 2028.
Predictable regulations in this small market make it relatively large and attractive.
Regulations are clear and so is the digital registration process and the rules regarding reliance.
For companies looking to develop pharmaceutical markets in the Andean and Southern Cone regions, Chile is a low-risk market to enter.
Generics-friendly and ageing in India’s favour
Chile’s prescription rules state that doctors are to identify drugs by their Denominación Común Internacional (DCI), their International Common Name.
Since Chileans do not give originator brand loyalty, DCI is a structural advantage for the growth of Chile generic drug market.
The Chilean population is ageing rapidly, and the prevalence of chronic diseases like cardiovascular disease, diabetes, and hypertension is increasing.
Once established, the Chilean market for affordable generics will provide opportunities to sustain long-term sales from India.
Given that the chronic-disease management prescription market is growing in Chile and that the Chilean market study suggests that the population continues to age, it is safe for pharmaceutical registration in Chile as a long-term investment rather than a short-term investment.
Learn more about Actiza’s Active Pharmaceutical Ingredients (APIs) and Finished Formulations. Evaluate whether your product fits this demand profile. Check out Actiza’s API Exports to Africa & LATAM to get a better idea of the regional market.
Why Chile Is Harder Than It Looks
In 2011, Chile’s medicines agency, ISP (via ANAMED) ‘Instituto de Salud Pública’, through its Agencia Nacional de Medicamentos was classified as a PAHO Regional Reference Authority of the Americas[3] (Nivel IV).
In terms of PAHO classification, this matters and means that ANAMED’s technical assessments are now trusted and relied upon by other regulatory bodies.
This means that ANAMED expects complete and thorough dossiers from applicants rather than self-serving dossiers, that is to say, a ‘rubber stamp’.
As far as Chile is concerned, every product, regardless of approvals in other markets, requires a full sanitary registration with the ISP to be marketed in Chile.
An FDA or EMA approval provides some useful background and can provide a faster review, but it does not avoid or replace registration.
Three main realities impact what follows in this guide.
First, foreign manufacturers are unable to hold a Chilean registration and must rely on a locally established Titular to do so.
Second, a WHO GMP certificate is not equivalent to a finding of a high-vigilance authority for all cases.
There is a lack of consensus on Chile’s own PIC/S status, and exporters should check the current ISP guidance for their site before making any presumption.
Third, the retail market you are entering is very concentrated. None of this makes Chile a bad market to enter.
It means that the first six months you spend there will be preparing the foundation for future sales rather than making sales.
The Barriers That Catch Exporters Out
You cannot register directly the local Titular
A foreign manufacturer cannot obtain a Chilean sanitary registration.
A local Titular (marketing-authorisation holder) or legal representative acting under Power of Attorney must possess and exercise the right on the exporter’s behalf before ISP.
As a result, selection of a Titular is greatly significant for an exporter since a Titular controls the registration, interfaces with ISP, and has the authority to control market access.
Registration transfer, exclusivity, and performance must be some of the rights that are negotiated before the start of the relationship as opposed to being addressed after the relationship is formed.
A WHO-GMP certificate is not an automatic shortcut
Chile offers abbreviated pathways under D.S. No. 3/2010 as long as products or components subject to overseas regulatory control are certified by regulatory authorities from certain high-vigilance countries.
Article 42(i) of the Agrarian and Agrifood Innovation Law allows the abbreviation of some, but not all, biotechnological product clinical studies if the product is similar to a product already registered in a country.
The Chilean PIC/S status diverges among regulatory intelligence sources.
One source indicates that Chile has been a full PIC/S member since 2017.
Another source says Chile’s current status is not a member of, applicant for, or even a pre-applicant of PIC/S.
Exporters cannot adopt either position, and should determine Chile’s current status for PIC/S and GMP recognition to find out what ISP will accept regarding their manufacturing site and then establish a registration timeline based on that information.
A WHO-GMP certificate is useful, but should not be viewed as a recognition of all Appendix 10 circumstances by a competent authority.
Bioequivalence required for a limited but expanding list
Bioequivalence is not a blanket requirement for generics in Chile. It applies to molecules on ISP’s bioequivalence list.
This list has grown since the implementation of Decreto Supremo 65/2019.
According to the Embassy of India’s most recent survey, about 3,440 products have been approved by ISP as bioequivalent.
The current list is not without its limitations, and traditionally, the testimony statements of industry representatives before the Senate’s health committee stated that bioequivalence coverage was around 29% of the pharmaceuticals[4] in Chile.
Traditionally, around 80% of the ‘bioequivalent’ products obtained this status by exemption rather than with a full study, as studies are costly.
ISP awards bioequivalence seals, and for molecules on the list, exporters are required to conduct a full comparative-bioavailability study at an ISP-approved centre, of which there are 9 in India.
For molecules not on the list, the requirements are less onerous; however, importers can expect to have quality documentation.
A retail market dominated by a small number of chains
Chile has a private pharmacy channel that is highly concentrated and has a documented history of price collusion investigations by the National Economic Prosecutor’s Office.
According to three industry sources, three major pharmacy chains control roughly 92% of the retail pharmacy[4] market in Chile.
According to the Embassy Report, independent pharmacies expanded at an impressive rate, growing from 1,276 outlets in 2019 to 1,940 in 2023,[5] a 52% increase.
Independent pharmacies also secured a procurement channel through CENABAST, showing that they are a competitive force within the market.
This report will be useful for your article. It outlines an increase in market concentration through an alternative procurement channel.
Regardless of the data source, access to the Chilean retail pharmacy market is concentrated in a small number of large buyers.
The more complicated and sophisticated nature of those buyers means that the value of Titular’s relationships is even greater.
The ISP Registration Pathway, Step by Step
Step 1: Appoint a local Titular / legal representative
Appoint a registered Chilean entity to hold registration and act as your importer of record by power of attorney. Determine the terms and conditions that will govern this relationship.
If, later, a partner assumes control of the registration, then what will happen to this relationship?
Until that time, the control of the Titular will enable it to continue to manage the exporter’s market access.
Step 2: Choose the right registration track
Determine whether the product will follow the standard procedimiento ordinario or Vía Abreviada.
Vía Abreviada allows submissions that have approvals from the FDA, EMA, MHRA, Swissmedic, Health Canada, PMDA or TGA (GlobalReg) as prior approval.
The selection makes a significant difference to the timeline and the scope of the dossier.
Based on the current ISP guidance, we must verify the recognised authority approvals that will qualify to assure a delivery date to any internal stakeholder.
Step 3: Compile the CTD dossier to ISP requirements
Develop a five-module CTD dossier based on Decreto Supremo 3/2010: administrative data, pharmaceutical quality (CMC), and safety and efficacy data, with a WHO-style Certificate of Pharmaceutical Product (COPP), a GMP certificate, a Certificate of Analysis, and stability data adequate for the climate of Chile.
Module 1 is country-specific and must be prepared according to the ISP outline, and it must be submitted via the online GICONA system (Embassy of India, Santiago).
Step 4: Establish bioequivalence where required
For molecules found on ISP’s bioequivalence list, a full comparative-bioavailability study is required; for molecules found off ISP’s bioequivalence list, the standard quality dossier may be submitted.
An entity other than ISP cannot award the bioequivalence seal.
Therefore, it is expected that the exporter will share the cost of the study with the importer.
Step 5: Submit through GICONA and respond to queries
Manage your application through ISP’s GICONA system. Be sure to respond to ISP’s evaluation queries promptly and as completely as possible.
The two most significant practical levers on the approval time are the completeness of the dossier and the speed of the exporter’s response to requests for information.
Step 6: Obtain the registration and set up compliant import
With approval, ISP generates an electronic Resolución Exenta to grant sanitary registration.
The Titular is now able to make imports.
This includes obtaining warehouse import health certificates, each batch analysis, filing an Import Declaration (DIN) with Chilean Customs, and, if necessary, applying bioequivalence seals on the Spanish-labelling (Embassy of India, Santiago).
In Chile, the timelines for registration depend on the pathway and source.
According to GlobalReg, it takes 120-240 days[6] to receive approval for pharmaceutical registration, whereas the Vía Abreviada reliance pathway is estimated to take around 90-180 days.
An industry source has mentioned that the standard legal evaluation would take approximately five to six months, but would be more like three months if the product had already been cleared by a high-surveillance authority (Farbe Firma).
Practitioners have mentioned that the timespan for the preparation of the dossier and feedback can take significantly longer than the legal-evaluation timings.
Please do not quote an expected approval time until you have confirmed which track the product falls under.
Documents and the Reliance Shortcuts
Core documentation for ISP registration
| Document | Purpose | Watch-out |
| CTD Dossier (Modules 1-5) | Full Technical, Quality, Safety & Efficacy Submission | Module 1 must follow ISP’s format; submitted via GICONA |
| Certificate of Pharmaceutical Product (COPP) | Indicates approval/marketing status of the country of origin | In WHO format; Apostilled for Chile |
| GMP Certificate | Manufacturing-related Quality | Confirm which ISP (International Standard Pharmaceuticals Inc.) basis will accept for the given site regarding recognition |
| Certificate of Analysis + Zone IVb Stability | Batch Quality & Hot/Humid Climate Shelf Life | For Chile filings, the expected Zone is IVb and not II |
| Bioequivalence / Therapeutic Equivalence Study | Required for the molecules on ISP’s bioequivalence list | Only ISP can grant the bioequivalence stamp |
| Local Titular Appointment & Apostilled Documents | Legal holder of the registration | A foreign manufacturer cannot hold the registration directly; Chile is a member of the Hague Apostille Convention, so a single apostille in general is sufficient |
Which track applies and how much it helps
| Track | When does it apply? | Effect |
| Ordinary Procedure (Ordinario) | Products without a qualifying recognized-authority approval | Full evaluation; takes longer |
| Vía Abreviada (Abbreviated) | Products approved by FDA, EMA, MHRA, Health Canada, PMDA, TGA, or Swissmedic | Less review required; confirm current eligibility and proof before filing |
| GMP Recognition Basis | Depends on the manufacturing site’s inspection history and certifications | Supports GMP verification, but the applicable basis should be confirmed with ISP given disputed PIC/S status |
The requirements for Chile’s readiness of the CTD dossier and GMP requirements of Chile intersect with India’s manufacturing base here: The Indian sites with approval from the FDA or EMA are best positioned to take the Vía Abreviada route so long as the current ISP eligibility criteria are met.
How Chile Actually Buys Medicine
A product can be registered to make it sellable.
If a product is registered, the next consideration will be the selling channel.
There are three main selling channels in Chile.
| Channel | Process | Impact on Exporter |
| Cenabast | As per data from the Embassy of India, Chile’s centralized public procurement agency is estimated to procure around 30% of the total distribution of pharmaceuticals in the country. It has the authority to procure medicines directly and import them where domestic supply and availability is poor. | Orders through competitive bidding; price-focused; requires registration along with a quality-assured and reliable supply chain. |
| GES/AUGE Plan and Ley Ricarte Soto | Ley Ricarte Soto and the Health Guarantees (Ley 19.966), along with the high-cost treatment fund (Law 20.850), guarantee access to treatment for a defined number of pathologies at particular evolutionary or complex stages, with quality assurance and procurement through Cenabast. | High assurance of quality and documentation; provides guaranteed demand for specified conditions. |
| Private Retail (Pharmacy Chains and Privately Owned Pharmacies) | A small number of large pharmacy chains control a majority of retail sales and outlets. The independent market is growing and using the services of Cenabast. | Market access is highly valued, and business relationships may carry significant weight alongside product quality. |
Cenabast has been given more power, including through reforms proposed under the “Ley de Fármacos 2” legislation process, to import medicines directly and to prioritise intermediary products to private and municipal pharmacies, largely as a response to the recurring shortages of bioequivalent generics.
For exporters, that particular reform of the legislation is in favour of registered, reliably supplied generics over speculative shipments.
Where India Fits
India’s structural advantages are in line with Chile’s actual requirements.
India hosts more U.S. The Food and Drug Administration (FDA) approved more drug manufacturing plants than any other country except the United States.
India is Chile’s third-largest provider of pharmaceuticals, with a 2023 share of 7.8% of all Chilean pharmaceutical imports.[7]
Imports from India were worth approximately US$176 million, an increase of 62.9% compared to five years earlier.
Indian manufacturers may have the opportunity to use several already existing regulatory systems.
For example, they may use a CTD format dossier as well as stability data that have been prepared for other regulated or tropical markets.
While Zone IVb stability data is not Chile-specific, as Chile is classified as a Zone II market, other dossiers may contain information relevant to India.
The adoption of Indian drugs by the Chilean market is likely to be favourable.
The Chilean market is dominated by the sale of generic drugs of paracetamol, losartan, and ibuprofen.
These are some of the largest markets and highest volumes, dominated by Indian API and finished-formulation capabilities.
That said, none of this avoids Indian company registrations through ISP, local Titular requirements, or bioequivalence where it applies.
India’s manufacturers are likely to meet Chile’s requirements sooner, and for less money, than most. This does not mean they can avoid them.
What This Means for a Quality-Assured Supplier
The Chile described in this guide has a small, high-standard market with a desire for generics; however, they are discerning.
Suppliers that do not have WHO-GMP credentials and/or recognised authority approvals will not be able to supply the Chilean market.
Suppliers that wish to serve this market need to be prepared with CTD (Common Technical Document) dossiers that include stability testing data for Zone IVb and bioequivalence studies for listed drugs.
Suppliers also need to maintain operational reliability of the Cenabast tenders and GES (Generic Enterprises S.A.) coverage.
Actiza has built a business to serve exactly this type of client- WHO-GMP Indian manufacturers for Level-IV reference regulators that supply APIs and formulated products along with the required supporting documentation for a CTD.
Review Actiza’s WHO-GMP, USFDA & EU-GMP credentials and quality systems, and see how CTD-dossier readiness supports generic tender timelines in Actiza’s ready-CTD-dossier resource.
FAQ
Q1. Who regulates pharmaceutical imports in Chile?
Required registrations and import permits for pharmaceuticals in Chile are undertaken by the Instituto de Salud Pública (ISP) (via ANAMED), under Decreto Supremo 3/2010, together with the Ministry of Health of Chile (MINSAL) (GlobalReg).
Q2. Can an Indian manufacturer register a medicine in Chile directly?
No. A manufacturer of medicines does not have the right to obtain a Chilean Sanitary Registration.
A Titular/Legal Representative, duly empowered by a power of attorney, has to hold the registration. The Representative will have to act directly with the ISP.
Q3. Does Chile accept FDA or EMA approval for faster registration?
A product may be registered via the expedited ‘Vía Abreviada’ route if it has received approval from one of the high-vigilance authorities, e.g. the FDA, EMA, MHRA, Swissmedic, Health Canada, PMDA or TGA.
Approval from one of these authorities is considered a positive approval background in the context of trade with Chile and is accepted as a substitution for a local approval.
Q4. Is bioequivalence required to sell generics in Chile?
Bioequivalence studies and approvals are required only for molecules that are currently on the bioequivalence list of ISP, published under Decreto Supremo 65/2019.
For these molecules, bioequivalence studies will be required and will be evaluated only by ISP.
For all other molecules, this requirement does not apply, and documentation regarding quality will still be needed.
Q5. How do public hospitals in Chile buy medicines?
Public pharmaceutical procurement through the centralised agency Cenabast is the primary procurement method.
Before and during the competing tender processes, Cenabast has the authority to manage the import of certain critical medicines and has the ability to prior supply of medicines to private and municipal pharmacies.
High-cost and priority conditions are also protected through the GES/AUGE guarantees and through the Ley Ricarte Soto fund, with related purchases then also needing to be procured through Cenabast.
Conclusion
Chile has potential for high rewards for a reasonable level of effort. The obstacles to entry discourage most companies from entering the market (for which they are thankful).
These barriers include a Level-IV PAHO reference regulator, a local Titular, a deadline for bioequivalence, and a concentrated retail supply chain. Companies that treat Chile as a soft market exit the country.
For Indian manufacturers that have a locally renowned regulator, Zone IVb, and a range of products that match the generic Chilean market, the pathway, whilst demanding, is clearly defined and creates a strong, high-value market that can lead to broader Andean region investment strategies.
Entering Chile in this way is worth the investment.
Contact us to find out how Actiza can assist you with the Chile & LATAM market → /contact/latam-market
To learn more about Actiza Pharmaceutical Pvt. Ltd., check out our Active Pharmaceutical Ingredients and Finished Formulations, as well as our credentials and quality systems in WHO-GMP, USFDA & EU-GMP, and our API Exports to Africa & LATAM, and our CTD-dossier preparation for generic tenders.
- https://www.drugpatentwatch.com/blog/regulatory-challenges-in-the-latin-american-generic-drug-market/?utm_source=chatgpt.com
- https://pharmexcil.com/uploads/files/CHILE_PHARMACEUTICAL_MARKET_REPORT.pdf
- https://www.globalreg.app/countries/CL
- https://www.pharmexec.com/view/country-report-chile
- https://www.indianembassysantiago.gov.in/pdf/PHARMACEUTICAL%20MARKET%20SURVEY%202-1.pdf
- https://www.globalreg.app/countries/CL
- https://pharmexcil.com/uploads/files/CHILE_PHARMACEUTICAL_MARKET_REPORT.pdf
